GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Radius Health Inc (NAS:RDUS) » Definitions » 14-Day RSI

Radius Health (Radius Health) 14-Day RSI : N/A (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Radius Health 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-28), Radius Health's 14-Day RSI is N/A.

The industry rank for Radius Health's 14-Day RSI or its related term are showing as below:

RDUS's 14-Day RSI is not ranked *
in the Drug Manufacturers industry.
Industry Median: 48.34
* Ranked among companies with meaningful 14-Day RSI only.

Competitive Comparison of Radius Health's 14-Day RSI

For the Drug Manufacturers - Specialty & Generic subindustry, Radius Health's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radius Health's 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Radius Health's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Radius Health's 14-Day RSI falls into.



Radius Health  (NAS:RDUS) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Radius Health  (NAS:RDUS) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Radius Health 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Radius Health's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Radius Health (Radius Health) Business Description

Traded in Other Exchanges
N/A
Address
22 Boston Wharf Road, 7th Floor, Boston, MA, USA, 02210
Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company's product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140. It primarily operates the business in the United States of America and generates key revenue from the sales of TYMLOS.
Executives
Willard H Dere director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Jean Pierre Garnier director UNITED TECHNOLOGIES CORP, 10 FARM SPRINGS ROAD, FARMINGTON CT 06032
Von Eschenbach Andrew C. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Jennifer Jarrett director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
G. Kelly Martin director, officer: CEO and President C/O NOVAN, INC., 4105 HOPSON RD, MORRISVILLE NC 27560
Sean Murphy director C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Elizabeth Messersmith officer: Senior Vice President 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Danielle Holtschlag officer: Vice President, Sales 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Chhaya Shah officer: Chief Business Officer 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Susan Vissers Lisa director 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000